Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.13
-0.02-0.12%
Pre-Market: 6:35 AM EDT
Comments
Loading...
Sabra Health Care REIT Analyst Ratings and Price Targets | NASDAQ:SBRA | Benzinga
Sabra Health Care REIT Inc has a consensus price target of $16.88 based on the ratings of 18 analysts. The high is $21 issued by Deutsche Bank on January 30, 2024. The low is $13 issued by Berenberg on July 27, 2023. The 3 most-recent analyst ratings were released by Truist Securities, Citizens Capital Markets, and Truist Securities on March 18, 2025, February 21, 2025, and January 17, 2025, respectively. With an average price target of $18.33 between Truist Securities, Citizens Capital Markets, and Truist Securities, there's an implied 7.02% upside for Sabra Health Care REIT Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Citizens Capital Markets
JMP Securities
Mizuho
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Sabra Health Care REIT
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 5.08% | Truist Securities | Michael Lewis70% | $17 → $18 | Maintains | Hold | Get Alert |
| 02/21/2025 | Buy Now | 16.75% | Citizens Capital Markets | Matthew Carletti84% | $20 → $20 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/17/2025 | Buy Now | -0.76% | Truist Securities | Michael Lewis70% | $18 → $17 | Downgrade | Buy → Hold | Get Alert |
| 01/07/2025 | Buy Now | 16.75% | JMP Securities | Aaron Hecht59% | → $20 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 12/05/2024 | Buy Now | 16.75% | Mizuho | Vikram Malhotra55% | $20 → $20 | Downgrade | Outperform → Neutral | Get Alert |
| 10/11/2024 | Buy Now | 5.08% | Scotiabank | Nicholas Yulico55% | $17 → $18 | Maintains | Sector Perform | Get Alert |
| 10/01/2024 | Buy Now | 16.75% | Wells Fargo | John Kilichowski44% | $16 → $20 | Assumes | Equal-Weight → Overweight | Get Alert |
| 09/13/2024 | Buy Now | 16.75% | Citigroup | Nicholas Joseph45% | $17 → $20 | Upgrade | Neutral → Buy | Get Alert |
| 09/04/2024 | Buy Now | 5.08% | Truist Securities | Michael Lewis70% | $16 → $18 | Maintains | Buy | Get Alert |
| 08/26/2024 | Buy Now | -0.76% | Scotiabank | Nicholas Yulico55% | $15 → $17 | Maintains | Sector Perform | Get Alert |
| 06/27/2024 | Buy Now | -6.6% | Truist Securities | Michael Lewis70% | $15 → $16 | Maintains | Buy | Get Alert |
| 05/15/2024 | Buy Now | -12.43% | Scotiabank | Nicholas Yulico55% | $14 → $15 | Maintains | Sector Perform | Get Alert |
| 01/30/2024 | Buy Now | 22.59% | Deutsche Bank | Omotayo Okusanya63% | → $21 | Initiates | → Buy | Get Alert |
| 01/03/2024 | Buy Now | -0.76% | Mizuho | Vikram Malhotra55% | $15 → $17 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | -6.6% | Stifel | Stephen Manaker44% | $14 → $16 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | -12.43% | Wells Fargo | Connor Siversky67% | $13 → $15 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | -6.6% | BMO Capital | John Kim62% | → $16 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | -12.43% | Wells Fargo | Connor Siversky67% | → $15 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 10/10/2023 | Buy Now | — | B of A Securities | Joshua Dennerlein49% | — | Upgrade | Neutral → Buy | Get Alert |
| 10/03/2023 | Buy Now | -6.6% | Wedbush | Richard Anderson64% | → $16 | Initiates | → Outperform | Get Alert |
| 09/20/2023 | Buy Now | -12.43% | Jefferies | Jonathan Petersen60% | $11 → $15 | Upgrade | Hold → Buy | Get Alert |
| 08/11/2023 | Buy Now | -18.27% | B of A Securities | Joshua Dennerlein49% | $11 → $14 | Upgrade | Underperform → Neutral | Get Alert |
| 07/27/2023 | Buy Now | -24.11% | Berenberg | Tao Qiu45% | → $13 | Initiates | → Hold | Get Alert |
| 07/14/2023 | Buy Now | -27.03% | Citigroup | Nicholas Joseph45% | $11 → $12.5 | Maintains | Neutral | Get Alert |
| 04/25/2023 | Buy Now | -24.11% | Barclays | Steve Valiquette53% | $15 → $13 | Maintains | Equal-Weight | Get Alert |
| 04/20/2023 | Buy Now | -35.79% | Wells Fargo | Connor Siversky67% | → $11 | Initiates | → Underweight | Get Alert |
| 04/19/2023 | Buy Now | -35.79% | Wells Fargo | Connor Siversky67% | → $11 | Initiates | → Underweight | Get Alert |
| 04/12/2023 | Buy Now | -24.11% | Credit Suisse | Omotayo Okusanya63% | → $13 | Reiterates | → Neutral | Get Alert |
| 03/29/2023 | Buy Now | -24.11% | Truist Securities | Michael Lewis70% | $14 → $13 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | -38.7% | Citigroup | Nicholas Joseph45% | $13 → $10.5 | Maintains | Neutral | Get Alert |
| 12/13/2022 | Buy Now | — | JMP Securities | Aaron Hecht59% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/14/2022 | Buy Now | -24.11% | B of A Securities | Joshua Dennerlein49% | $15 → $13 | Downgrade | Neutral → Underperform | Get Alert |
| 10/10/2022 | Buy Now | -24.11% | Baird | David Rodgers59% | → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 06/30/2022 | Buy Now | -18.27% | Jefferies | Jonathan Petersen60% | $15 → $14 | Downgrade | Buy → Hold | Get Alert |
| 05/25/2022 | Buy Now | -12.43% | Mizuho | Vikram Malhotra55% | $16 → $15 | Upgrade | Neutral → Buy | Get Alert |
| 04/18/2022 | Buy Now | -18.27% | Barclays | Steve Valiquette53% | $16 → $14 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/04/2022 | Buy Now | -12.43% | Credit Suisse | Omotayo Okusanya63% | $14 → $15 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Sabra Health Care REIT (SBRA) stock?
The latest price target for Sabra Health Care REIT (NASDAQ:SBRA) was reported by Truist Securities on March 18, 2025. The analyst firm set a price target for $18.00 expecting SBRA to rise to within 12 months (a possible 5.08% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
The latest analyst rating for Sabra Health Care REIT (NASDAQ:SBRA) was provided by Truist Securities, and Sabra Health Care REIT maintained their hold rating.
When was the last upgrade for Sabra Health Care REIT (SBRA)?
The last upgrade for Sabra Health Care REIT Inc happened on January 7, 2025 when JMP Securities raised their price target to $20. JMP Securities previously had a market perform for Sabra Health Care REIT Inc.
When was the last downgrade for Sabra Health Care REIT (SBRA)?
The last downgrade for Sabra Health Care REIT Inc happened on January 17, 2025 when Truist Securities changed their price target from $18 to $17 for Sabra Health Care REIT Inc.
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a maintained with a price target of $17.00 to $18.00. The current price Sabra Health Care REIT (SBRA) is trading at is $17.13, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.